MedTrace Logo

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

NCT02968368 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2020-11-02

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD

Conditions

  • Renal Insufficiency, Chronic
  • Iron-Deficiency Anemia

Interventions

DRUG

Ferric maltol

OTHER

Placebo

Sponsors & Collaborators

  • Shield Therapeutics

    lead INDUSTRY

Principal Investigators

  • Mark Sampson, MBChB · Shield Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2018-01-18
Completion
2018-10-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02968368 on ClinicalTrials.gov